Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Consensus Target Price from Analysts

Akero Therapeutics, Inc. (NASDAQ:AKRO) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $75.86.

Several analysts recently commented on the company. UBS Group raised their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. HC Wainwright raised their price target on Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Morgan Stanley lifted their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Canaccord Genuity Group boosted their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th.

Insider Buying and Selling

In other Akero Therapeutics news, CFO William Richard White sold 2,817 shares of Akero Therapeutics stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $86,735.43. Following the sale, the chief financial officer now directly owns 38,335 shares in the company, valued at approximately $1,180,334.65. The trade was a 6.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Patrick Lamy sold 925 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $28,480.75. Following the sale, the vice president now directly owns 17,858 shares in the company, valued at $549,847.82. This trade represents a 4.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 198,992 shares of company stock worth $9,134,713. 7.94% of the stock is owned by corporate insiders.

Institutional Trading of Akero Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after acquiring an additional 446 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after purchasing an additional 450 shares during the last quarter. Hsbc Holdings PLC raised its stake in shares of Akero Therapeutics by 8.5% during the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock worth $220,000 after purchasing an additional 621 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Akero Therapeutics by 1.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company’s stock valued at $1,153,000 after buying an additional 637 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its stake in shares of Akero Therapeutics by 5.0% in the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock valued at $584,000 after buying an additional 1,000 shares in the last quarter.

Akero Therapeutics Trading Down 2.1 %

Shares of NASDAQ AKRO opened at $49.45 on Friday. Akero Therapeutics has a twelve month low of $17.86 and a twelve month high of $58.40. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of -13.19 and a beta of -0.11. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average is $35.35 and its 200-day moving average is $31.05.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.